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LETTER TO THE EDITOROral Proliferative Verrucous
Leukoplakia (PVL) in a
post-Bone Marrow
Transplant Patient
Hematopoietic stem cell transplantation (HSCT)
procedures require immunosuppression, and have
been associated with an increased risk of postthera-
peutic secondary malignancies [1]. Squamous cell
carcinoma (SCC) is 1 of the malignancies that can
occur in oral mucosa tissues after immunosuppres-
sive therapies such as HSCT [2]. Risk factors that
can contribute to the elevated risk of oral cancer in
these patients include aggressive conditioning regi-
mens, the occurrence and treatment of graft-versus-
host disease (GVHD), opportunistic infections of
the oral mucosa by oncogenic viruses [1,2], and de-
fective DNA based repair diseases such as Fanconi
anemia (FA) [3]. Proliferative verrucous leukoplakia
(PVL) was described by Hansen et al. [4] in 1985, and
is characterized by white, irregular, and local or multi-
focal patches of the oral mucosa. These lesions are re-
fractory to conventional treatment, and have a high
tendency to undergo malignant transformation. Al-
though there is little data regarding the etiopathogen-
esis of PVL, preliminary epidemiologic data show
a higher incidence among women (74%) after the sixth
decade of life, with 37% of the women citing tobacco
usage. Approximately 75% of PVL lesions progress
to SCC in a median period of almost 8 years following
diagnosis [4].
In April 2007, a 40-year-old male presented to an
oral medicine consultation complaining of an exten-
sive palatal and gingival lesion. Oral examination re-
vealed a large plaque covering the entire hard
palatal mucosa and on the anterior vestibular gingiva.
The palatal lesion had a verrucous white surface and
showed some areas of brown pigmentation. The le-
sion was posterior, limited to the keratinized tissue,
and did not extend into the soft palate (Figure 1B).
The regular, white surface of the gingival lesion ex-
tended from the left maxillary first molar to the right
maxillary first molar, and seemed to respect the muco-
gingival line (Figure 1A). A second verrucous and ho-
mogeneous white plaque was detected on the right
posterior third of the buccal mucosa and retromolar
area, and a third small plaque was noted on the infe-
rior buccal gingiva. The patient indicated that the
gingival and palatal lesions were symptomatic, espe-cially during mastication and palpation. The patient’s
medical history included an allogeneic bone marrow
transplant (BMT) procedure conducted in a Japanese
HSCT reference hospital in September 1997 for
treatment of acute myelogenous leukemia (AML) in
remission. The conditioning regimen consisted of cy-
clophosphamide (Cy) (120 mg/kg) and busulfan (Bu)
(16 mg/kg). Cyclosporine (CsA) was reported as the
exclusive agent for GVHD prophylaxis. A moderate
clinically diagnosed oral chronic GVHD (cGVHD)
lesion was described as the most important post-
BMT complication. An oral biopsy undertaken in
November 1998 showed oral hyperkeratosis but re-
vealed no other histologic features of cGVHD. At
this time the patient’s chief complaint was painful
oral mucosa. In March 2004, the patient was identi-
fied with a palatal lesion and referred for oral surgical
tissue collection, which resulted in a histologic diag-
nosis of papilloma. In 2006, the patient required addi-
tional treatment of his oral condition and sought
treatment from a tertiary bucomaxillofacial service.
Maxillary and palatal lesions were submitted to a sec-
ond incisional biopsy, which was histologically de-
scribed as ‘‘lichenoid reaction without atypias.’’ The
patient failed to continue treatment and denied fur-
ther collection of oral samples because of an increased
fear of surgery. By early 2007, the patient’s oral con-
dition had worsened, and required a course of 55 mg
of prednisone to control a chronic skin GVHD that
had been diagnosed a few months earlier. At our
oral medicine outpatient unit, the patient was advised
to undergo an oral surgical sampling of the lesions,
and samples were collected at the gingival and palatal
sites. The 02 gingival and 03 palatal specimens were
characterized histologically as presenting hyperkera-
tosis, koilocytosis, and an absence of cellular atypias
(Figs. 1C and D). A direct imunofluorescence was un-
dertaken in 1 of the palatal surgical specimens and re-
sults were negative for IgM, IgG, IgA, and C3. These
data, combined with the patient’s medical history,
previous biopsies, and clinical presentation, resulted
in a diagnosis of PVL. Based on the extent of the
mass and thrombocytopenic findings, an attempt to
control lesion growth by laser surgical ablation was
performed. One month postablation, clinical evalua-
tion showed a recurrence of the oral lesions, thus
prompting a reference for the patient to a head and
neck surgeon to receive more extensive resection of
the lesion masses.
PVL is a relatively new clinical form of oral
leukoplakia that has no classical histologic descrip-
tion available, making its diagnosis more difficult.1197
1198 Biol Blood Marrow Transplant 14:1197-1199, 2008Letter to the EditorFigure 1. (A) Extensive white plaque on buccal gingival. Lesion is limited to keratinized tissue. (B) Extensive verrucous plaque on hard palate. Lesion is
limited to keratinized tissue. (C) Histologic sections demonstrated hyperplasia of the spindle cell layer (acanthosis), and excess surface parakeratin (he-
matoxylin-eosin stain, original magnification: 100). (D) Histologic sections showed dyskeratosis, koilocytes, and characteristic hypergranulosis of the
stratum spinosum (hematoxylin-eosin stain, original magnification: 400).Diagnosis is mostly based on clinical observations,
as well as longitudinal clinical and histologic obser-
vations [4,5]. After a review of the international lit-
erature published on PVL, the present report
appears to be the first to describe a PVL case in
a post-BMT patient. Post-BMT patients have been
identified to have higher risks for oral malignancies.
Case reports and larger retrospective observational
studies suggest that patients with cGVHD also have
higher risks for developing solid malignancies, includ-
ing SCC [6,7]. Patient risk is characterized as being de-
pendent on the immunosuppressive regimen (drugs
and dosage) instituted for GVHD prophylaxis and
treatment. Moreover, oral GVHD seen in post-BMT
patients is clinically and histopathologically similar to
oral lichen planus (OLP). Although OLP malignant
potential is controversial, there are increasing reports
of SCC arising fromOLP lesions [8]. In the present re-
port it is difficult to isolate variables responsible for the
development of PVL in this patient. It is reasonable to
hypothesize, however, that immunosuppressive regi-
mens and cGVHD persistence over a long period of
time after receiving a BMT procedure could have had
significant roles in the development of this PVL case.
There are also controversial opinions regarding the
role of oncogenic viruses, such as HPV-16, in the gen-
esis of PVL lesions [5]. In the present case, histologic
analysis indicated the presence of koilocytes, although
no attempt was made to detect HPV in tissue samples
because of economic constraints. PVL is considered
a potentially malignant lesion that can progress to
SCC or verrucous carcinoma (VC) in approximately75% of cases [4]. No information from previous biop-
sies, or histologic aspects from specimens collected at
our unit, could confirm epithelial dysplasia or cGVHD
in this patient. Tobacco and alcohol use, strongly asso-
ciated with carcinogenesis in classical SCC of the oral
cavity, does not seem to be necessary for the develop-
ment or progression of PVL.
Surgical laser excision has been suggested for the
treatment and/or control of PVL [4]. However, recur-
rences of PVL lesions after surgical laser excision have
been reported in many cases. Immediate recurrence of
lesions in ablated areas suggests that oral PVL lesions
should be more aggressively treated. Attempts to con-
trol lesion size in the present case were not successful,
which reinforces the recommendations that PVL
should be closely monitored for recurrence and malig-
nant transformation.
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